Politicians accuse US food agency of illegally monitoring employees


© Shutterstock

Republican leaders on two key congressional committees have concluded in a new report that the US Food and Drug Administration (FDA) illegally monitored email communications sent by whistleblowers in the agency.

Representative Darrell Issa, who chairs the House of Representatives’ oversight and government reform committee, and Senator Charles Grassley, the top Republican on the senate judiciary committee, issued a staff report concluding that the FDA spied on its employees ‘without regard’ for their rights to communicate with Congress. On top of this, the agency’s email monitoring policies ‘do not provide safeguards to protect whistleblowers from retaliation’.

The Republican staff analysis of the events that led six of the FDA’s own scientists and doctors to sue the agency in January 2012 for spying on them for two years, and subsequently retaliating against them for expressing safety concerns about the approval process for medical devices. Two were fired and another two did not get their contracts renewed, according to their attorneys.

The lawsuit, which alleged that the FDA began its electronic snooping campaign after learning that the whistleblowers had written to the then president elect, Barack Obama, in early 2009, is still pending.

‘The FDA’s surveillance was not lawful, to the extent that it monitored communications with Congress and the Office of Special Counsel (OSC),’ the Republican report concluded. ‘Federal law protects disclosures to OSC and Congress.’ The OSC is an independent agency charged with protecting federal employees and applicants from prohibited practices, such as reprisals for whistleblowing.

But, at a February 26 hearing of the oversight and government reform committee, its top Democrat, Representative Elijah Cummings, noted that another report released just a day earlier by the FDA’s parent agency, the Department of Health and Human Services, paints a different picture.

This report concluded that the FDA had ‘reasonable concern’ that confidential information, including possibly trade secrets, had been disclosed by agency employees. ‘In our interviews of those conducting the computer monitoring and our review of other data sources, we found no evidence that FDA had obtained or used passwords to any of the scientists’ private email accounts, nor did we find any evidence that FDA logged into any of the scientists’ computers,’ the report notes.

In addition, the office determined that the FDA had provided notice to its scientists and others that all data on its computer network was monitored. Moreover, no evidence was found that the FDA’s actions constituted retaliation.

Nevertheless, the report concluded that the FDA should have sought legal advice beforehand to assess whether its use of ‘potentially intrusive computer monitoring’ was appropriate and consistent with ‘constitutional and statutory limitations’ on government searches.

Related Content

Whistleblowers accuse FDA of spying, persecution

3 February 2012 News Archive

news image

US FDA employees sue agency, saying they were subjected to secret surveillance for expressing safety concerns about medical d...

Chinese scientist arrested for attempted research theft

9 April 2013 News and Analysis

news image

Medical College of Wisconsin researcher arrested for allegedly stealing a patented cancer compound to take to a Chinese unive...

Most Read

UC Davis chemist sentenced to four years over explosion

19 November 2014 News and Analysis

news image

Postdoc sentenced over attempt to make explosive device and reckless disposal of hazardous waste

Grad student blamed for research misconduct at Utah

13 November 2014 News and Analysis

news image

Two papers have been retracted due to image falsification at the University of Utah

Most Commented

Beetle behind breath test for bank notes

17 November 2014 Research

news image

Photonic crystal inks inspired by longhorn beetle could help to fight counterfeiting

Bayer wins race to buy Merck & Co consumer care

9 May 2014 Business

news image

$14bn deal will make Aspirin inventor the number two over-the-counter healthcare company